Latest stories on BDTX
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
StockTitan52 · neutralproduct/pr
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire52 · neutralproduct/pr
Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript
Seeking Alpha58 · neutralproduct/pr
Black Diamond Therapeutics price target raised to $14 from $8 at Stifel
The Fly64 · neutralanalyst
Black Diamond Therapeutics GAAP EPS of -$0.17
Seeking Alpha42 · neutralearnings
Black Diamond Therapeutics, Inc. (BDTX) files 8-K
SEC 8-K50 · neutralgeneral
Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy
Seeking Alpha58 · neutralanalyst
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
StockTitan55 · neutralgeneral
Black Dragon Texas Frac Sand Acquisition Stays on Track as Share Buyback Nears
InvestorsHub63 · neutralgeneral
Black Dragon Texas Frac Sand Acquisition Stays on Track as Share Buyback Nears
Yahoo Top58 · neutralgeneral
Raymond James Keeps Outperform Rating On Black Diamond Therapeutics After Q2
The Fly56 · neutralanalyst
Black Diamond Therapeutics setup ‘attractive,’ says Jefferies
The Fly63 · neutralanalyst
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
StockTitan67 · bullishearnings
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Seeking Alpha67 · bullishproduct/pr
Black Diamond Therapeutics, Inc. (BDTX) files 8-K
SEC 8-K50 · neutralgeneral
BDTX Phase 2 Silevertinib Results Update Scheduled—Key Milestone Approaches for EGFRm NSCLC Therapy
MarketChameleon58 · neutralproduct/pr
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference | BDTX Stock News
StockTitan55 · neutralgeneral